Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
2021
2020
2019
ASCO 2021 - Breast Cancer
ASCO 2021 Wrap-Up - Breast Cancer
ASCO 2020 - Lung Cancer
ASCO 2020 - Wrap Up
ASH 2020 - Multiple Myeloma
SABCS 2020 Highlights
ASH 2019 Post Wrap-Up
ASH 2019 Multiple Myeloma
The Janssen CarePath Program and the Cost of Care
By
Leslie Lauersdorf, ARNP
Conference Correspondent
,
ASH
Conference Correspondent
Leslie Lauersdorf has seen the Janssen CarePath Program help alleviate some of the financial burden of treatment for her patients.
Read More ›
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Conference Correspondent
,
ASH
Conference Correspondent
Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Read More ›
Meta-Analysis to Compare Efficacy of Treatment Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Conference Correspondent
,
ASH
Conference Correspondent
Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.
Read More ›
Results of an Early Access Treatment Protocol of Daratumumab in US Patients with Relapsed or Refractory Multiple Myeloma
Conference Correspondent
,
ASH
Conference Correspondent
An early access study confirms the safety and preservation of health-related quality of life of daratumumab in multiple myeloma.
Read More ›
Potentiation of Antimyeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide, or Bortezomib via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP
Conference Correspondent
,
ASH
Conference Correspondent
Combinations of targeted agents that include daratumumab offer synergy to alter the tumor microenvironment to promote the efficacy of these combinations in the treatment of multiple myeloma.
Read More ›
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with 1 Line of Prior Therapy
Conference Correspondent
,
ASH
Conference Correspondent
PREAMBLE is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with 1 line of prior therapy.
Read More ›
Response-Adapted Therapy for Newly Diagnosed Myeloma
Conference Correspondent
,
ASH
Conference Correspondent
A leading cancer clinic has developed an innovative response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.
Read More ›
Phase 1b Study to Assess Subcutaneous Daratumumab in Patients Relapsed or Refractory Multiple Myeloma
Conference Correspondent
,
ASH
Conference Correspondent
Preliminary data suggest that subcutaneous delivery of daratumumab in patients with relapsed/refractory multiple myeloma is well-tolerated and yields similar response rates to intravenous administration of the drug.
Read More ›
Phase 3 Study: Daratumumab in Combination with Lenalidomide plus Dexamethasone Induces Clonality Increase and T-Cell Expansion
Conference Correspondent
,
ASH
Conference Correspondent
Daratumumab in combination with lenalidomide plus dexamethasone specifically induces robust increases in T-cell clonality. The finding provides support for an immune modulatory mechanism of daratumumab.
Read More ›
Natural History of Relapsed/Refractory Myeloma: A Multicenter Study
Conference Correspondent
,
ASH
Conference Correspondent
Outcomes of patients with relapsed/refractory multiple myeloma are poor, but are improving as treatment options expand.
Read More ›
Page 26 of 31
21
22
23
24
25
26
27
28
29
30
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION